Stockscreener 앱 받기
31.32
3.20%
0.97
시간 외 거래:
31.32
Veracyte Inc 주식(VCYT)의 최신 뉴스
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care - Curetoday
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - BioSpace
Veracyte launches prostate metastatic test - MSN
Crafting an Individual Treatment Plan for Patients With Prostate Cancer - Curetoday
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Veracyte launches metastatic prostate cancer test - Investing.com
Veracyte launches metastatic prostate cancer test By Investing.com - Investing.com South Africa
Veracyte launches prostate metastatic test (VCYT:NASDAQ) - Seeking Alpha
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier L - GuruFocus
Veracyte Announces Expanded Availability of Decipher Prostate Te - GuruFocus
Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer - marketscreener.com
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer | VCYT Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Veracyte Announces Multiple Abstracts Demonstrating Power of Dec - GuruFocus
Breakthrough Cancer Insights: 18 New Studies Confirm Veracyte Decipher Test's Power in Prostate and Bladder Cancer - Stock Titan
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - 01net
Veracyte data joins NCI SEER database for research By Investing.com - Investing.com South Africa
Veracyte Announces Decipher Prostate Genomic Classifier Results - GuruFocus
Veracyte data joins NCI SEER database for research - Investing.com
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release | VCYT Stock News - GuruFocus
Should You Continue to Hold Veracyte Stock in Your Portfolio? - MSN
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - 01net
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 | VCYT Stock News - GuruFocus
Cancer Diagnostics Leader Veracyte Announces Q1 2025 Earnings Date: Key Updates Coming May 7 - Stock Titan
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why Veracyte (VCYT) is a Strong Growth Stock - Yahoo Finance
Veracyte And 2 More Stocks That Might Be Trading Below Their Estimated Value - Yahoo Finance
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago - MSN
Veracyte (VCYT) Just Overtook the 20-Day Moving Average - Yahoo Finance
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? - Nasdaq
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating By Investing.com - Investing.com South Africa
Guggenheim cuts Veracyte stock price target to $37, keeps Buy rating - Investing.com Australia
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Veracyte Scores Relative Strength Rating Upgrade; Hits Key Threshold - MSN
Veracyte (VCYT) Introduces AI-Powered Cancer Detection – Faster and More Accurate Than Ever! - Insider Monkey
9 AI News and Ratings on Investors’ Radar - Insider Monkey
Craig-Hallum bullish on Veracyte, initiates with a Buy - MSN
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade - Yahoo
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - 01net
Veracyte Cancer Diagnostic Platform Shows Higher Specificity Than Blood Tests - MarketScreener
0.34%
0.46%
자본화:
|
볼륨(24시간):